Filter by: Subject

Filter by: Subject

Results Per Page:

Positron emission tomography/computed tomography (PET/CT) (9)
SDG-03: Good health and well-being (7)
Positron emission tomography (PET) (6)
Tuberculosis (TB) (6)
Prostate cancer (5)
Theranostics (4)
Human immunodeficiency virus (HIV) (3)
Molecular imaging (3)
Nuclear medicine (3)
Oncology (3)
Prostate specific membrane antigen (PSMA) (3)
Radiochemistry (3)
68Ga-nitroimidazole PET/CT (2)
Coronavirus disease 2019 (COVID-19) (2)
COVID-19 pandemic (2)
Fluorodeoxyglucose (FDG) (2)
Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) (2)
Health sciences article SDG-03 (2)
Hypoxia (2)
Maximum standard uptake value (SUVmax) (2)
Metabolic parameters (2)
Metastatic castration-resistant prostate cancer (mCRPC) (2)
Overall survival (OS) (2)
Prostate specific antigen (PSA) (2)
Radiomics (2)
Radionuclides (2)
Single photon emission computed tomography (SPECT) (2)
Targeted radionuclide therapy (TRT) (2)
Total lesion glycolysis (TLG) (2)
18F-fuorodeoxyglucose (FDG) (1)
225Ac-PSMA-617 (1)
68Ga-hypoxia imaging (1)
68Ga-nitroimidazole (1)
68Ga-PSMA PET/CT (1)
68Gallium prostate specific membrane antigen (68Ga-PSMA) (1)
[68Ga]Ga-FAPI (1)
[68Ga]Ga-NODAGARGD (1)
Actinium-225-labeled prostate-specific membrane antigen ([225Ac]Ac-PSMA-617) (1)
Africa (1)
Androgen deprivation treatment (ADT) (1)
Angiotensin receptor blockers (ARBs) (1)
Angiotensin-converting enzyme (ACE) (1)
Anti-tuberculous treatment (ATT) (1)
Apoptosis (1)
Biochemical recurrence (1)
Bladder cancer (1)
Carcinoma, squamous cell (1)
Cardiometabolic disorders (1)
Castration-resistant prostate cancer (1)
cFLFLF (1)
CXCR4 (1)
DDR kinases (DDRi) (1)
Deoxyribonucleic acid (DNA) (1)
Development (1)
Diagnosis (1)
Differentiation (1)
Disease management (1)
DNA damage repair (DDR) (1)
DNA repair inhibitors (1)
Education (1)